Paris, France – In a significant advancement for the treatment of pulmonary embolism (PE), Jupiter Endovascular has unveiled groundbreaking pivotal trial data for its innovative Vertex pulmonary embolectomy system. The results, presented at the prestigious EuroPCR 2026 congress held from May 19-22 in Paris, demonstrate the system’s exceptional ability to not only remove blood clots but also to significantly improve the often-devastating strain on the right side of the heart. This pioneering technology, featuring a proprietary transforming fixation (TFX) platform, is poised to redefine the management of this life-threatening condition.
The SPIRARE II trial, a 123-patient study, was meticulously designed to assess the safety, effectiveness in improving right heart function, and overall clinical outcomes for patients treated with the Vertex system. The trial’s findings have exceeded expectations, meeting both primary endpoints and offering a beacon of hope for patients suffering from severe PE.
Breakthrough Technology at the Forefront of PE Treatment
At the heart of Jupiter Endovascular’s success lies its proprietary transforming fixation (TFX) platform. This innovative technology is engineered to overcome critical challenges in navigating the delicate vasculature of the heart and lungs. Traditional methods often grapple with the inherent conflict between the need for flexible catheter manipulation and the requirement for stable support during procedures. The Vertex system, powered by TFX, effectively decouples these two crucial aspects, allowing for both intricate navigation through the right heart into the pulmonary arteries and a secure, controlled intervention at the site of the obstruction.
This advanced capability is specifically designed to simplify the complex process of PE intervention, addressing long-standing issues related to cardiac strain, over-reliance on guidewires, and the difficulty in achieving reliable vessel access. The TFX platform’s unique design promises to make the thrombectomy procedure more predictable, efficient, and ultimately, safer for patients.
SPIRARE II Trial: A Testament to Vertex’s Clinical Impact
The SPIRARE II trial (NCT06576427) focused on a patient population with a high degree of haemodynamic severity, underscoring the real-world applicability and robust performance of the Vertex system. A striking 54% of participants presented with normotensive shock, a critical indicator of the heart’s struggle to pump blood effectively. Furthermore, a substantial 93% were classified into the C3 or D2 risk categories according to the stringent 2026 American College of Cardiology and American Heart Association (ACC/AHA) PE guidelines. These classifications represent the most severe forms of PE, often associated with a grim prognosis.
The trial’s primary endpoints were designed to rigorously evaluate the system’s impact on the strained right ventricle. A key metric employed was the right ventricle to left ventricle (RV/LV) ratio, a critical diagnostic marker that quantifies the degree of strain on the right heart. This ratio is instrumental in assessing the severity of PE, understanding its impact on cardiac function, and guiding treatment decisions.
Key findings from the SPIRARE II trial include:
- Significant Haemodynamic Recovery: The Vertex system achieved a remarkable mean reduction of 0.39 in the RV/LV ratio at just 48 hours post-procedure. This reduction signifies a substantial reversal of right heart strain, indicating that the intervention effectively alleviated the pressure overload on the right ventricle.
- Low Major Adverse Event Rate: The trial reported an impressively low major adverse event (MAE) rate of 2.4%, highlighting the safety profile of the Vertex system even in a high-risk patient cohort. This low rate is crucial for any device intended for use in complex cardiovascular interventions.
- Beyond Clot Extraction: Data revealed that TFX-enabled thrombectomy went beyond simply removing the obstructing clot. It also led to meaningful afterload reduction and improved right heart function, as evidenced by positive changes in pulmonary artery pressures and vascular resistance. This suggests a systemic benefit that addresses the underlying haemodynamic consequences of PE.
Expert Endorsement and Clinical Significance
The implications of these findings have resonated deeply within the cardiology community. Dr. Catalin Toma, Director of Interventional Cardiology at the UPMC Heart and Vascular Institute and a co-principal investigator of the SPIRARE II trial, expressed his enthusiasm for the results. "The SPIRARE II results are especially impressive, recognizing the haemodynamic severity of the patient population," Dr. Toma stated. "The ability of TFX-enabled thrombectomy to deliver consistent, reproducible recovery across all patient classifications is something we believe was achieved by having stable, controlled access to target vessel obstructions."
Dr. Toma’s comments underscore the practical advantages of the TFX platform, emphasizing its role in achieving reliable access and controlled intervention, which are paramount in complex procedures. The consistent recovery observed across diverse patient profiles suggests that the Vertex system offers a predictable and effective solution for a wide spectrum of severe PE cases.
A New Paradigm in Understanding Pulmonary Embolism
Jupiter Endovascular’s CEO, Carl J. St. Bernard, articulated the company’s vision for how these findings will shape the future of PE management. He highlighted that the SPIRARE II trial was not merely designed to meet regulatory requirements but to generate a "robust clinical dataset that includes paired invasive haemodynamics and detailed patient-level data" across a population of elevated severity.
"We believe these findings will contribute to a growing understanding of PE as a complex cardiovascular disease centred on right heart dysfunction and haemodynamic compromise, not defined by clot burden alone," Bernard explained. This perspective shifts the focus from solely treating the physical obstruction to comprehensively addressing the cascading haemodynamic effects of PE, particularly the critical impact on the right heart. This more holistic approach is vital for improving patient outcomes and long-term survival.
The Chronology of Innovation and Validation
The journey of the Vertex system from concept to clinical validation is a testament to sustained innovation in cardiovascular device development. While specific timelines for the initial development of the TFX platform are not detailed in the provided text, the culmination of this effort is evident in the successful execution and positive outcomes of the SPIRARE II trial.
The presentation of these late-breaking results at EuroPCR 2026, a leading global congress for interventional cardiovascular medicine, signifies a crucial milestone. The event draws together leading clinicians, researchers, and industry innovators, providing a platform for the dissemination of cutting-edge scientific advancements. The inclusion of Jupiter Endovascular’s data among the top-tier presentations at EuroPCR 2026 underscores the significance and impact of their work.
The EuroPCR congress, held annually, serves as a critical forum for the exchange of knowledge and the discussion of emerging technologies. For EuroPCR 2026, the dates of May 19-22 in Paris marked a period of intense scientific discourse. The inclusion of the SPIRARE II trial data in this esteemed setting highlights its readiness for broader clinical adoption and its potential to influence treatment guidelines.
Supporting Data and Future Directions
The SPIRARE II trial’s success is rooted in its rigorous methodology and the collection of comprehensive data. The focus on the RV/LV ratio as a primary endpoint, supported by detailed haemodynamic measurements, provides objective evidence of the Vertex system’s efficacy. The fact that this ratio improved significantly at 48 hours post-intervention suggests a rapid and sustained positive impact on cardiac function.
The trial’s adherence to the latest ACC/AHA PE guidelines for risk stratification further validates the study’s relevance and the severity of the patient population treated. This ensures that the observed benefits are not merely in milder cases but in those with the highest risk of mortality and morbidity.
Beyond the immediate haemodynamic benefits, the observation of improved pulmonary artery pressures and vascular resistance suggests a more profound impact on the pulmonary vasculature, potentially leading to long-term improvements in lung function and exercise capacity for patients.
Broader Implications and the Competitive Landscape
The success of Jupiter Endovascular’s Vertex system at EuroPCR 2026 positions it as a significant player in the evolving landscape of PE treatment. While this article focuses on Jupiter’s breakthrough, it is important to acknowledge the broader context of innovation in cardiovascular interventions. The mention of Boston Scientific presenting data on its SEISMIQ 4CE Coronary IVL catheter for calcified coronary artery disease at the same congress highlights the dynamic nature of the medical device industry, with multiple companies striving to advance patient care through technological innovation.
However, Jupiter’s focus on addressing the complex haemodynamic sequelae of PE, particularly right heart strain, represents a specialized and critical area of unmet need. The Vertex system’s ability to directly impact this aspect of the disease sets it apart and offers a compelling alternative or adjunct to existing treatment modalities.
The implications for clinical practice are substantial. If the Vertex system can consistently deliver these results in larger, real-world settings, it could lead to:
- Reduced Mortality and Morbidity: By effectively treating severe PE and mitigating right heart strain, the system has the potential to significantly lower mortality rates and reduce long-term complications associated with the disease.
- Shorter Hospital Stays and Faster Recovery: Improved haemodynamic function and a lower incidence of complications could translate into shorter hospitalizations and a quicker return to normal activities for patients.
- Expanded Treatment Options: The system’s safety and efficacy may allow for earlier intervention in high-risk PE patients, potentially preventing irreversible cardiac damage.
- Refined Clinical Guidelines: The robust data generated by the SPIRARE II trial could influence future clinical guidelines for the management of severe PE, placing greater emphasis on haemodynamic recovery and right heart function.
As Jupiter Endovascular continues to advance its technology and pursue regulatory approvals, the Vertex system, powered by its transformative TFX platform, stands as a promising development poised to significantly improve the lives of patients battling pulmonary embolism. The positive results presented at EuroPCR 2026 mark a pivotal moment, signalling a new era in the treatment of this critical cardiovascular condition.
About the Author
